Evidence map›Paper›PMID 32354917›Full record

ArticleIn vivo (Athens, Greece)

Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection.

Ryo Saito, Hidetake Amemiya, Naohiro Hosomura, Hiromichi Kawaida, Suguru Maruyama, Hiroki Shimizu, Shinji Furuya, Hidenori Akaike, Yoshihiko Kawaguchi, Makoto Sudo and 3 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07658586 (A Comprehensive Study of Liver Cancer Diagnosis and Prognosis Prediction Based on Artificial Intelligence and Multimodal Data), which is not on this map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07658586 active not recruitingnot on this map

A Comprehensive Study of Liver Cancer Diagnosis and Prognosis Prediction Based on Artificial Intelligence and Multimodal Data

TypeobservationalSponsorGuangxi Medical UniversityRan2025 to 2028Enrolled600ConditionsLiver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ryo SaitoFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Hidetake AmemiyaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Naohiro HosomuraFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Hiromichi KawaidaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Suguru MaruyamaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Hiroki ShimizuFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Shinji FuruyaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Hidenori AkaikeFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Yoshihiko KawaguchiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Makoto SudoFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Shingo InoueFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Hiroshi KonoFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Daiduke IchikawaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan dichikawa@yamanashi.ac.jp.
University of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe high rate of recurrence and repetitive features of hepatocellular carcinoma (HCC) require specific treatment strategies. This study aimed to evaluate the long-term outcomes of recurrent HCC focusing on clinicopathological factors. PATIENTS AND

methodsA total of 104 patients who were treated with re-hepatectomy, radiofrequency ablation (RFA) or transcatheter arterial chemoembolization for recurrent HCC were analyzed. Post-recurrent prognoses were compared between each treatment group based on the presence of adverse prognostic factors (APFs) identified.

resultsIn the hepatectomy group, the prognosis of patients with APFs was significantly worse compared to those without APFs. By contrast, the survival rate of patients who underwent RFA was not significantly different from those with and without APFs.

conclusionOur results demonstrate the heterogeneity that exists in terms of the long-term survival of patients with recurrent HCC. The treatment strategy for recurrent HCC should be based on the assessment of presence of APFs to improve long-term prognosis.

Indexed as

AgedAged, 80 and overCarcinoma, HepatocellularCombined Modality TherapyDisease ManagementFemaleHepatectomyHumansLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisSurvival RateTreatment OutcomehepatectomyHepatocellular carcinomarecurrence

Identifiers

PMID32354917
PMCPMC7279801
OpenAlexW3022989520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.